The argument for the importance of patient diagnosis often relies upon the efficacy of subsequent treatment. But according to a recent study, three-quarters of people would want to know if they have a particular neurological disorder even if it had no cure.
Biocept is bringing on a veteran GE Healthcare and Quest Diagnostics executive to guide the company's insurance reimbursement and medical contract strategy.
General Electric's $2 billion commitment to invest in Africa includes the launch of a program to train biomedical engineering technicians in Nigeria, where patients are dying of treatable conditions because the devices to treat them are left unfixed due to a lack of know-how, according to a prominent nongovernmental organization.
General Electric is launching healthcare initiatives in Africa in partnership with governments and a $20 million commitment from the GE Foundation to improve the continent's healthcare. Most notably, the GE Foundation is funding a $1.5 million biomedical training program in Nigeria to ensure that the country has technicians who can fix devices ranging from blood pressure cuffs to X-rays.
GE Healthcare's imaging agent Vizamyl is on the verge of European approval as a tool to help diagnose Alzheimer's disease, something that could help counter challenges to build momentum for the product in the U.S.
GE Healthcare won FDA approval for its automated breast imaging system for women with dense breast tissue, continuing its ongoing campaign to develop innovative cancer diagnostics and imaging technologies.
GE Healthcare and MRI software provider CorTechs Labs signed a joint-marketing agreement on a MRI scanning solution used in conjunction with CorTech's NeuroQuant program.
GE Healthcare is rolling out its FDA-approved Vizamyl, an imaging agent designed to spotlight Alzheimer's-tied buildups in PET scans, but reimbursement uncertainty paints a murky picture of the product's commercial future.
GE Healthcare has been no stranger to dealmaking over the past year, and the company's CEO said it has no plans to let up.
Despite heavy competition, GE Healthcare will forge ahead with its ongoing acquisition spree, division chairman and CEO John Dineen has said. Execs are continuing their search for more information technology and life sciences diagnostic deals to help enhance the company's edge.